An interventional study of Evaluation of the staging of fibrosis liver and Determine the expression level of semaphorin in Non Alcoholic Fatty Liver Disease, sponsored by Centre Hospitalier Universitaire de Nice. Completed at 1 site in France. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-03-31.
Sponsored by Centre Hospitalier Universitaire de Nice · Not applicable, Interventional, and Basic science
Recent epidemiological studies in France showed a high prevalence of obesity (14.5%) and its strong increase in the last 20 years. Among the many complications associated with obesity, liver complications (steatosis and steatohepatitis [NASH]) are among the most common. Semaphorins were described in the early 1990. More than 20 types of these proteins have been reported to date. These proteins were used for neural development. Since many functions have also been described. The semaphorins are involved in numerous physiological or physiopathological processes (cardiac morphogenesis, vascular growth, tumor progression), the regulation of immune cells and liver fibrosis. Preliminary studies have allowed to show that dendritic cells infiltrate adipose tissue and initiate the activation of T cells and inflammation. Immune semaphorin are new players in the regulation of inflammation and immune reactions.
The role of immune semaphorin in regulating inflammation in the two compartments (liver and adipose tissue) could be a crucial step that could lead to more severe liver damage. Its dysregulation could explain NASH injuries. The goal is to identify a new mode of regulation of cellular homeostasis in the fatty liver disease. These factors may serve as diagnostic markers or future therapeutic targets.
1,474 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 303 are open to participants now.
This study's enrollment of 148 is above the median of 60 across 1,072 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Browse Non-alcoholic Fatty Liver Disease studies →Centre Hospitalier Universitaire de Nice is the lead sponsor of 709 studies on the registry; 176 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Morbid obese patients
Inclusion Criteria:
Exclusion Criteria:
Other: Evaluation of the staging of fibrosis liver · Other: Determine the expression level of semaphorin · Other: Determination of the composition of immunity cells
Other: Evaluation of the staging of fibrosis liver · Other: Determine the expression level of semaphorin · Other: Determination of the composition of immunity cells
Other: Evaluation of the staging of fibrosis liver · Other: Determine the expression level of semaphorin · Other: Determination of the composition of immunity cells
The investigators will determine the severity of steatosis, inflammation and fibrosis by histological study of liver biopsies
The investigators will determine the expression level (gene and protein) of immune semaphorin and their (s) receptor (s) in the liver and subcutaneous and visceral adipose tissue by RT-PCR,
The investigators determine the composition of immunity cells by immunohistochemical and biochemical analyses (Western Blotting )
Evaluation of the staging of liver fibrosis
The investigators determine the stage of liver fibrosis by histological study of biopsies
Time frame: Day 0
Determination of the expression of level of semaphorin
The investigators determine by technic of Reverse Transcription Polymerase Chain Reaction (RT-PCR) the expression of level of semaphorin
Time frame: Day 0
Determination of the composition of immunity cells
The investigators determine the composition of immunity cells by Immunohistochemical and biochemical analyses (Western Blotting)
Time frame: Day 0
Plan to share: No
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Non-alcoholic Fatty Liver Disease→
Centre Hospitalier Universitaire de Nice